2011 Press Releases

Allergan Reassures Patients and Surgeons of the Quality and Safety of Its Breast Implant Devices Sold and Distributed Worldwide  

Health Canada approves BOTOX® as prophylactic treatment for chronic migraine  

Allergan Reports Third Quarter Operating Results  

Award-winning Actress Courtney Thorne-Smith and Allergan, Inc. Reveal Changes in Women's Perceptions of BOTOX Cosmetic Over Nearly a Decade  

Allergan Announces Quarterly Conference Call  

National Headache Foundation, HealthyWomen and Allergan Offer People Living With Chronic Migraine a Chance to "Rewrite Your Day"  

BOTOX® (onabotulinumtoxinA) Receives U.S. FDA Approval for the Treatment of Urinary Incontinence in Adults with Neurological Conditions Including Multiple Sclerosis and Spinal Cord Injury  

Allergan's BOTOX® Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury  

Allergan Reports Second Quarter 2011 Operating Results  

Allergan, Inc. to Acquire Privately Held Dermatologic Company, Vicept Therapeutics  

Allergan Announces Quarterly Conference Call  

Allergan Receives FDA Approval for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA)  

New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes  

Christina Hendricks Kicks Off the Latisse® Wishes Challenge with the Goal of Raising $500,000 for the Make-A-Wish Foundation®  

Allergan Launches Open Letter to Congress to Kick-Off the 2011 C.H.O.I.C.E. Campaign  

Allergan and Molecular Partners Enter into an Exclusive License Agreement For MP0112 For the Treatment of Retinal Diseases  

Allergan Reports First Quarter 2011 Operating Results  

New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions  

Allergan Announces Quarterly Conference Call  

Allergan Board of Directors Announces Departure of President F. Michael Ball; Chairman of the Board and Chief Executive Officer David E.I. Pyott Resumes Role as President